32 completed, 6 withdrawn, 5 terminated, 4 unknown. 48 Phase 3, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 48 | Completed 32, Withdrawn 6, Terminated 5, Unknown 4, Recruiting 1 |
| Phase 2 | 9 | Completed 5, Terminated 3, Unknown 1 |
Follow Dyspnea: new trials by email Literature Review of Dyspnea trials Research Report on Dyspnea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2) Berobenatide, Placebo - Apnea, Sleep Disorders | Phase 3 | Recruiting | Pfizer | 258 | 2026-10-19 | 2026-11-06 |
| Efficacy of Nebulised Inhalational Steroids in Neonates With Meconium Aspiration Syndrome Budesonide, Normal Saline - Meconium Aspiration Syndrome | Phase 3 | Completed | Khyber Teaching Hospital | 60 | 2025-11-28 | 2026-08-13 |
| Reducing Breathlessness With Dronabinol in COPD Patients Dronabinol 2.5mg Capsule, Placebo - COPD, Breathlessness | Phase 3 | Completed | Vejle Hospital | 30 | 2025-02-26 | 2026-10-05 |
| The Impact of Inhaled Furosemide and Perorally Administered Levodropropizine on Dyspnea in Patients With Respiratory Diseases Furosemide 40 mg, Levodropropizine, Placebo - saline - Dyspnea | Phase 2 / Phase 3 | Unknown | University Hospital Hradec Kralove | 102 | 2024-02-27 | 2024-04-16 |
| The Addition of Inhaled Furosemide to Standard Treatment of COPD Exacerbation Furosemide, Normal saline - Chronic Obstructive Pulmonary Disease Exacerbation, COPD Exacerbation | Phase 3 | Unknown | American University of Beirut Medical Center | 200 | 2023-03-01 | 2023-03-15 |
| Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19 ZYESAMI™ (aviptadil acetate), Placebo, Nebulized administration of ZYESAMI™ or Placebo - SARS-CoV 2, COVID | Phase 3 | Withdrawn | APR Applied Pharma Research s.a. | 2021-12-15 | 2026-05-14 | |
| Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19 ZYESAMI™ (aviptadil acetate), Placebo, Nebulized administration of ZYESAMI™ or Placebo - SARS-CoV 2, COVID | Phase 2 / Phase 3 | Terminated | APR Applied Pharma Research s.a. | 144 | 2021-02-15 | 2023-02-03 |
| Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With COVID-19 Standard COVID-19 care, Quercetin Phytosome - COVID-19 | Phase 3 | Completed | Liaquat University of Medical & Health Sciences | 152 | 2020-09-29 | 2021-04-22 |
| MultiStem Administration for COVID-19 Induced ARDS (MACoVIA) MultiStem, Placebo - ARDS | Phase 2 / Phase 3 | Terminated | Healios K.K. | 22 | 2020-04-28 | 2026-10-16 |
| Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial Hydroxychloroquine and azithromycin treatment, conventional management of patients - COVID19 | Phase 3 | Withdrawn | Hospital St. Joseph, Marseille, France | 2020-04-01 | 2020-11-20 | |
| Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma NVA237 (glycopyrronium bromide), Placebo - Asthma | Phase 2 / Phase 3 | Completed | Novartis Pharmaceuticals | 148 | 2017-05-04 | 2019-01-16 |
| A Long-term Safety Study of QVM149 in Japanese Patients With Asthma QVM149 - Asthma | Phase 3 | Completed | Novartis Pharmaceuticals | 96 | 2017-04-28 | 2020-04-07 |
| A Long-term Safety Study of QMF149 in Japanese Participants With Asthma QMF149 - Asthma | Phase 3 | Completed | Novartis Pharmaceuticals | 51 | 2017-04-25 | 2020-02-07 |
| Study of Safety of QAW039 in Patients With Asthma Inadequately Controlled on Standard-of-care Asthma Treatment QAW039 150 mg, QAW039 450 mg, Placebo - Asthma | Phase 3 | Terminated | Novartis Pharmaceuticals | 2538 | 2017-03-21 | 2020-10-12 |
| Breathlessness Exertion and Morphine Sulphate Placebo, Morphine Sulfate, Plus laxative (Docusate with senna) - Chronic Obstructive Pulmonary Disease, Dyspnea | Phase 3 | Completed | Flinders University | 171 | 2016-08-08 | 2020-02-11 |
| Bronchodilator's Effects on Exertional Dyspnoea in Pulmonary Arterial Hypertension Nebulized ipratropium bromide, Nebulized combination ipratropium bromide with salbutamol, Nebulized Placebo - Pulmonary Arterial Hypertension | Phase 3 | Withdrawn | Assistance Publique - Hôpitaux de Paris | 2016-07-01 | 2020-01-29 | |
| Efficacy and Safety Study of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment. QAW039, Placebo - Asthma | Phase 3 | Completed | Novartis Pharmaceuticals | 894 | 2015-12-11 | 2026-10-07 |
| FIRST-line Support for Assistance in Breathing in Children (FIRST-ABC) Feasibility Study Treatment strategy: Non-invasive respiratory support delivered via high flow nasal cannula, Treatment strategy: Non-invasive respiratory support delivered via continuous positive airway pressure - Hypoxia, Respiratory Acidosis | Phase 2 / Phase 3 | Completed | Great Ormond Street Hospital for Children NHS Foundation Trust | 121 | 2015-11-01 | 2016-12-16 |
| Opioids for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease Morphine sulfate, Placebo - Chronic Obstructive Pulmonary Disease, Dyspnea | Phase 3 | Withdrawn | Flinders University | 2015-05-01 | 2016-01-12 | |
| Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy Eleclazine, Placebo - Hypertrophic Cardiomyopathy | Phase 2 / Phase 3 | Terminated | Gilead Sciences | 172 | 2015-02-05 | 2018-09-24 |
Showing 20 of 48. Sign in to see all of them.
Pulmonary Disease, Chronic Obstructive (14) · Asthma (8) · Heart Failure (8) · Cardiomyopathies (4) · COVID-19 (3) · Motor Activity (3) · Renal Insufficiency (3) · Acute Lung Injury (2) · Bronchiolitis (2) · Dyspnea, Paroxysmal (2) · Hypertension, Pulmonary (2) · Hypoxia (2) · Respiratory Distress Syndrome (2) · Acidosis, Respiratory (1)
Pathological Conditions, Signs and Symptoms (48) · Respiration Disorders (48) · Respiratory Tract Diseases (48) · Signs and Symptoms (48) · Signs and Symptoms, Respiratory (47) · Lung Diseases (33) · Lung Diseases, Obstructive (24) · Pathologic Processes (17) · Chronic Disease (14) · Disease Attributes (14) · Cardiovascular Diseases (11) · Immune System Diseases (11) · Bronchial Diseases (10) · Hypersensitivity (9) · Heart Diseases (8)
Natriuretic Peptide, Brain (4) · Furosemide (3) · Morphine (3) · Saline Solution (3) · Albuterol (2) · Epinephrine (2) · Salmeterol Xinafoate (2) · aviptadil (2) · fevipiprant (2) · Adrenal Cortex Hormones (1) · Analgesics, Opioid (1) · Budesonide (1) · Buspirone (1) · Continuous Positive Airway Pressure (1) · Dioctyl Sulfosuccinic Acid (1)
Novartis Pharmaceuticals (7) · Scios, Inc. (4) · Assistance Publique - Hôpitaux de Paris (3) · APR Applied Pharma Research s.a. (2) · Amphastar Pharmaceuticals, Inc. (2) · Flinders University (2) · American University of Beirut Medical Center (1) · Baqiyatallah Medical Sciences University (1) · Bayside Health (1) · Cambridge University Hospitals NHS Foundation Trust (1) · Centre Hospitalier Universitaire de la Réunion (1) · Duke University (1) · Genentech, Inc. (1) · Gilead Sciences (1) · GlaxoSmithKline (1)
United States (16) · Australia (7) · France (7) · Germany (7) · United Kingdom (6) · Canada (5) · Spain (5) · Belgium (4) · Brazil (4) · Japan (4) · Lithuania (4) · Netherlands (4) · Argentina (3) · China (3) · Czechia (3)
David C Currow, MD, PhD (2) · Jonathan C Javitt, MD, MPH (2) · Ajay Mahal, PhD (1) · Amanda Peppercorn, MD (1) · Anne E Holland, PhD (1) · Capucine Morelot, MD, PhD (1) · Carl Fichtenbaum, MD (1) · Celso Carvalho, Dr. (1) · Christine F McDonald, PhD (1) · Denis E O'Donnell, MD, FRCPC (1) · Dennis Jensen, Ph. D. (1) · Don C Rockey, MD (1)
PMID 10400005, PMID 31959019, PMID 16183441, PMID 19910177, PMID 21367594, PMID 21536936, PMID 21599896, PMID 21732835, PMID 21805159, PMID 22497823, PMID 22946546, PMID 23032196, PMID 23471469, PMID 23770519, PMID 23899930, PMID 24011178, PMID 24054337, PMID 24176997, PMID 24464687, PMID 24521787, PMID 24622005, PMID 25074507, PMID 25281655, PMID 25358424, PMID 26304935, PMID 26685116, PMID 26988350, PMID 27044249, PMID 27623769, PMID 27654854, PMID 27672116, PMID 28606907, PMID 28641792, PMID 28716797, PMID 29431103, PMID 29781109, PMID 29866165, PMID 30316548, PMID 30354576, PMID 30688793, PMID 31239657, PMID 31418515, PMID 31606362, PMID 31760132, PMID 31846014, PMID 32375747, PMID 32636851, PMID 32745548, PMID 32979986, PMID 33179911
2008 (1), 2014 (1), 2015 (1), 2016 (1), 2018 (1), U10CA037420 (1)